Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Dr. Hana Hybasek Dzurikova
1. July 2024

Hyperacute T-Waves: A Comprehensive Pattern Exploration

Hyperacute T-Waves: A Comprehensive Exploration

Hyperacute T waves are an important but poorly understood ECG feature of acute coronary occlusion (ACO) myocardial infarction 1,2

By dissecting their defining characteristics, diagnostic challenges, and clinical implications, the article aims to equip readers with a comprehensive understanding of hyperacute T-waves and their relevance in cardiovascular medicine, particularly as a STEMI equivalent and a diagnostic feature of ACO myocardial infarction3.

Defining Hyperacute T-Waves Criteria

The term hyperacute T waves is meant to describe a diagnostic feature of the T waves in the early progression of ECG findings caused by ACO.  There is no accepted, universal definition of hyperacute T-waves, but experts describe them as symmetrically enlarged or inflated T waves compared to their QRS complex, and they could likely be defined as an elevation in the ratio of the area under the ST-segment and T-wave compared to the area/size of the QRS complex.

Hyperacute T-Waves: A Comprehensive Pattern Exploration
Hyperacute T-Waves: A Comprehensive Pattern Exploration

STEMI Equivalents: Play It Safe with Certified AI

Hyperacute T-Waves: A Comprehensive Pattern Exploration
Hyperacute T-Waves: A Comprehensive Pattern Exploration

While some groups have described hyperacute T-waves simply as tall (absolute amplitude) recent research by Smith et al. challenges this oversimplified characterization. Their editorial reviewed recent evidence showing that raw T wave amplitude did not correlate with myocardial infarction diagnosis, but T wave amplitude relative to the preceding R wave was remarkable in distinguishing anterior benign early repolarization patients from subtle left anterior descending acute occlusion patients. 

Furthermore, Smith and Meyers showed high specificity and diagnostic accuracy of expert-subjective hyperacute T waves (which they described as a ratio of area under the T wave compared to the QRS amplitude) in a large blinded cohort of potential ACS patients in the ED5

 hyperacute T waves with reciprocal negative hyperacute T wave
Figure: Inferior hyperacute T waves with reciprocal negative hyperacute T wave in lead aVL (Dr.Smith’s  ECG Blog, digitized by PMcardio)

Morphological Considerations

In addition to their increased height and breadth, hyperacute T waves have a more symmetric appearance compared to normal T-waves. Due to the increasingly broad base of the T wave, the QT interval also lengthens, which has been separately documented as one of the first observable measurement changes in acute coronary occlusion6.

Hyperacute T-Waves: A Comprehensive Pattern Exploration
Figure: Large and symmetric T-waves observed in leads I, aVL and V2-V5 diagnostic of proximal LAD occlusion (Dr.Smith’s  ECG Blog, digitized by PMcardio)
Hyperacute T-Waves: A Comprehensive Pattern Exploration
Figure: Hyperacute T-waves present in leads V1-V4, along with ST elevation in leads V1 and V2, and ST depression observed in leads II, III, aVF, V5, and V6, indicative of LAD occlusion (Dr.Smith’s  ECG Blog, digitized by PMcardio)

Diagnostic Challenges and Comparisons

Hyperacute T-waves present diagnostic challenges that require careful consideration and comparison with baseline ECGs. While some cases may present with unequivocal hyperacute T-waves, others demand a comparative analysis to baseline morphology to discern subtle changes indicative of evolving myocardial ischemia. This comparative approach allows clinicians to differentiate between hyperacute T-waves associated with acute coronary syndromes and other T-wave abnormalities of benign origin7.

It’s important to note that hyperacute T-waves, indicative of early MI, can sometimes be mistaken for T-wave changes associated with hyperkalemia, where serum potassium levels exceed 5.5 mEq/L, leading to characteristic narrow, peaked T-waves, particularly notable in leads V2 and V38

Hyperacute T-Waves: A Comprehensive Pattern Exploration
Figure: Peaked T waves in hyperkalemia (Dr.Smith’s  ECG Blog, digitized by PMcardio)
Hyperacute T-Waves: A Comprehensive Pattern Exploration
Figure: T waves indicative of hyperkalemia, characterized by their pointed peaks, “tented” shape, very flat ST segment, and a prolonged QRS duration (114 ms), making them pathognomonic signs of this condition (Dr.Smith’s  ECG Blog, digitized by PMcardio)

Localization and Reciprocal Changes

One of the key characteristics of hyperacute T-waves is their localization within the affected coronary distribution. These T-waves typically manifest in the territory supplied by the occluded coronary artery and may exhibit focal reciprocal changes mirroring the ischemic insult. This reciprocal pattern extends outward from the epicenter of the occlusion, reflecting the spatial extent of ischemic injury. By recognizing these localization patterns, clinicians can gain valuable insights into the underlying pathology and guide appropriate management strategies9.

Differential Diagnosis and Reciprocal Reperfusion T-Waves

Distinguishing true hyperacute T-waves from other T-wave abnormalities, particularly reciprocal reperfusion T-waves, is essential for accurate diagnosis and management. Reciprocal reperfusion T-waves may masquerade as hyperacute T-waves but typically emerge post-reperfusion, accompanied by diminishing pain. Clinicians should carefully evaluate the clinical context and ECG findings to differentiate between these entities and to determine appropriate treatment plans10

Clinical Implications and Management Strategies

Prompt recognition and appropriate management are essential to mitigate the risk of adverse cardiac events and optimize patient outcomes. Healthcare providers should initiate a comprehensive evaluation, including serial ECG monitoring, cardiac biomarkers, and imaging studies, to confirm the diagnosis and assess the extent of myocardial injury. Emergent reperfusion therapies are paramount in optimizing patient outcomes and reducing morbidity and mortality associated with ACO11,12.

Hyperacute T-Waves: A Comprehensive Pattern Exploration
Hyperacute T-Waves: A Comprehensive Pattern Exploration

Can you interpret this ECG?

It’s 11:30 PM, and a 67-year-old male patient presents with two hours of ongoing chest pain. Would you refer for an emergent coronary angiography?

Hyperacute T-Waves: A Comprehensive Pattern Exploration

Enhancing ECG Interpretation and Care Consistency with AI

Recognizing hyperacute T-waves as STEMI equivalents underscores the critical importance of early intervention in optimizing patient outcomes13. However, identifying them correctly can be challenging due to their nuanced presentation and potential overlap with other ECG abnormalities. 

In this context, for healthcare personnel with varied experience and skills in interpreting ECGs, specializing in Occlusion Myocardial Infarction (OMI), the PMcardio OMI AI Model offers cutting-edge technology designed to augment the chest pain patients’ journey. This innovative solution is not only aimed at assisting in the accurate identification of subtle ischemic patterns, potentially overlooked in standard evaluations, but also ensures that each patient receives the same high standard of care when it comes to ECG diagnosis. By integrating advanced algorithms, PMcardio offers consistency in the interpretation of complex ECG patterns across different healthcare providers and settings, thereby enhancing the precision and reliability of OMI detection and supporting equitable care delivery.

Dr. Stephen W. Smith, Dr. H. Pendell Meyers, and Dr. Robert Herman insights into the (Occlusion Myocardial Infarction) OMI AI model.

Concluding Insights on Hyperacute T-Waves

In this review, we’ve untangled the complexities of hyperacute T-waves to equip healthcare professionals with the essential knowledge for their accurate identification, diagnosis, and effective management. Much remains to be studied and understood about hyperacute T waves.

Our aim is to facilitate the adoption of consistent and precise ECG interpretation standards across patient care, ensuring that every individual receives a uniform level of diagnostic accuracy. Highlighting the integration of advanced technologies, like the OMI AI ECG model, underscores our commitment to supporting healthcare providers in achieving this goal, as we envision a standardized approach to ECG interpretation that benefits patients universally.

This article was edited by Dr. H. Pendell Meyers.

Hyperacute T-Waves: A Comprehensive Pattern Exploration
Hyperacute T-Waves: A Comprehensive Pattern Exploration

Pin Down STEMI Equivalents with Certified AI

Hyperacute T-Waves: A Comprehensive Pattern Exploration
Hyperacute T-Waves: A Comprehensive Pattern Exploration

References

  1. Smith SW. The ECG in Acute MI: An Evidence-Based Manual of Reperfusion Therapy. Springer; 2008.
  2. Smith SW. Hyperacute T-waves: Understanding the ECG signs of early myocardial infarction. Dr. Smith’s ECG Blog. Available from: https://hqmeded-ecg.blogspot.com/[specific-post-url]. Accessed April 9, 2024.
  3. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-269.
  4. Wagner GS, Marriott HJL. Marriott’s Practical Electrocardiography. 12th ed. Lippincott Williams & Wilkins; 2014.
  5. Smith SW. Hyperacute T-waves Can Be a Useful Sign of Occlusion Myocardial Infarction if Appropriately Defined. Ann Emerg Med. 2023 Mar 3. doi: 10.1016/j.annemergmed.2023.01.011.
  6. Kenigsberg DN, Khanal S, Kowalski M, Krishnan SC. Prolongation of the QTc Interval Is Seen Uniformly During Early Transmural Ischemia. J Am Coll Cardiol. 2007 Mar 6;49(9):1299-305. doi: 10.1016/j.jacc.2006.11.035.
  7. Libby P, Bonow RO, Mann DL, Zipes DP. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Elsevier; 2015.
  8. Somers MP, Dressler W, Nable JV, Keeley EC. The prominent T wave: electrocardiographic differential diagnosis. Am J Emerg Med. 2002 May;20(3):243-51
  9. de Winter RJ, Verouden NJ, Wellens HJ, Wilde AA. A new ECG sign of proximal LAD occlusion. N Engl J Med. 2008;359(19):2071-3.
  10. Otto C. Textbook of Clinical Echocardiography. 5th ed. Elsevier; 2013.
  11. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-e425.
  12. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (updating the 2007 guideline and replacing the 2011 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126:875-910.
  13. Powerful Medical. Powerful Medical Website. Available from: https://www.powerfulmedical.com/. Accessed April 10, 2024.

Dr. Hana Hybasek Dzurikova

Dr. Hana Hybasek Dzurikova is a medical educator driving innovation and change in health professions education through technology-enhanced learning.
Dr. Hana Hybasek Dzurikova is a medical educator driving innovation and change in health professions education through technology-enhanced learning.
About PMcardio:

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

Powerful Medical team receiving the MedTech Innovator 2025 Mid-Stage Grand Prize award on stage, holding a large winner’s check.

Powerful Medical Wins MedTech Innovator 2025

Powerful Medical has been named MedTech Innovator 2025, winning MTI’s Mid-Stage Grand Finals—top honor from the world’s largest medtech accelerator. The award recognizes PMcardio and its FDA Breakthrough-designated Queen of Hearts™ AI ECG technology, which doubles sensitivity for detecting severe heart attacks and significantly cuts ECG-to-balloon time in large clinical trials.

PMcardio Reports Positive RCT Results and Late-Breaking Clinical Science for STEMI Detection

PMcardio’s AI-powered ECG technology delivers breakthrough results at TCT 2025—improving heart attack detection, reducing false activations, and enabling faster treatment across major clinical trials, including the landmark DIFOCCULT-3 RCT.

Join over 100,000 healthcare professionals who are already taking advantage of AI

All Supported ECG Findings

Rhythms
Sinus bradycardia • Sinus rhythm • Sinus tachycardia • Paced rhythm • Atrial fibrillation
Atrial fibrillation with rapid ventricular response • Atrial fibrillation with slow ventricular response • Atrial flutter • Atrial flutter with rapid ventricular response • Atrial flutter with slow ventricular response • Supraventricular tachycardia • Suspected junctional rhythm • Suspected junctional bradycardia • Suspected accelerated junctional rhythm • Wide QRS rhythm • Idioventricular rhythm • Wide QRS tachycardia

Myocardial Infarctions
  • STEMI
  • STEMI
    Equivalent
Detects occlusive myocardial infarctions (OMIs) even without ST elevation (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.)
  • High-Risk NSTEMI
    Represents a type 1 myocardial infarction caused by a transiently recanalized coronary occlusion—classically seen in patterns such as Wellens type A or B due to subtotal LAD obstruction, but possible in any infarct-related territory.
  • Culprit Detection
    AI-predicted likelihood scores for LAD, LCx, and RCA with 3D heart visualization highlighting the predicted culprit artery.

Conduction Abnormalities (Heart Blocks
1st degree AV block • 2nd degree AV block, type Wenckebach • Higher degree AV block • Complete right bundle branch block • Incomplete right bundle branch block • Complete left bundle branch block • Incomplete left bundle branch block • Nonspecific intraventricular conduction delay • Left anterior fascicular block • Left posterior fascicular block • Bifascicular block (RBBB + LAFB) • Bifascicular block (RBBB + LPFB) • Trifascicular block (RBBB + LAFB + AVBLOCK1) • Trifascicular block (RBBB + LPFB + AVBLOCK1)

LVEF
Reduced LVEF (≤40%) • Mildly reduced LVEF (41 – 49%) • No signs of reduced LVEF (≥50%)

Axis
Left cardiac axis deviation • Right cardiac axis deviation • Extreme cardiac axis deviation • Normal axis

Measurements
Heart rate • P wave • PR interval • QRS duration • QT interval • Corrected QT interval (Framingham formula) • RR interval • PP interval • ST elevations

Other Supported Diagnoses
Suspected long QT syndrome • Suspected short QT syndrome • Suspected atrial enlargement • Suspected ventricular hypertrophy • Premature complexes

Dr. Tom De Potter, MD

Cardiologist at the Cardiac Center Aalst

Cardiologist specializing in Pacemaker Device Therapy and Electrophysiology. Leads the electrophysiology unit at the Heart Center in Aalst, holds an executive board position at the European Heart Academy, and serves as EHRA scientific program committee co-chair.

Dr. Martin Penicka, MD, PhD

Cardiologist at the Cardiac Center Aalst

Cardiologist at the Cardiac Center Aalst since 2009, specializing in non-invasive imaging and valvular disease. Fellow of the European Society of Cardiology (FESC) and the European Association of Cardiovascular Imaging (FEACVI).

Dr. Ward Heggermont, MD, PhD

Co-director at the Cardiovascular Center

Co-director at the Cardiovascular Center of Aalst Hospital, specializing in heart failure. Research focus at the intersection of cardiology, virology, and metabolism.

Prof. Dr. Robert Hatala, PhD

Co-founder and Chief Scientist

Head of the Arrhythmia and Pacing department at the National Institute of Cardiovascular Diseases in Slovakia. More than 150 publications and 10,000 citations. Contributor to ESC clinical practice guidelines and executive editor of the European Heart Journal since 2020.

Arieh Levy

Head of PMcardio for Individuals

Arieh leads the PMcardio for Individuals product at Powerful Medical, guiding its development as a clinical tool for emergency physicians, cardiologists, and primary care physicians. He holds a First Class MEng in Biomedical Engineering from Imperial College London, where he specialised in AI for cardiology, building physics-informed neural networks to model atrial electrical properties, giving him a background that bridges the clinical and technical demands of building a certified AI medical device used at the bedside every day.

Dr. Dave Pearson, MD​

Chief Medical Officer

Academic emergency medicine physician, entrepreneur, investor, and researcher with nearly two decades at Atrium Health, one of US largest health systems. Brings expertise at the intersection of clinical care, healthcare innovation, and strategic leadership.

Prof. Stephen W. Smith, MD

Professor of Emergency Medicine

Faculty physician in Emergency Medicine at Hennepin County Medical Center and Professor of Emergency Medicine at the University of Minnesota. Co-inventor of the OMI paradigm and editor of Dr. Smith’s ECG Blog, the most-visited US-based ECG interpretation blog.

Prof. Emanuele Barbato, MD, PhD

President of EAPCI

Interventional cardiologist specializing in coronary artery disease and coronary physiology. Acting president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and contributor to the clinical practice guidelines for STEMI care.

Scott Sharkey, MD

Chief Medical Officer

Chief Medical Officer of the Minneapolis Heart Institute Foundation and practicing cardiologist at Allina Health Minneapolis Heart Institute. Co-founder of the STEMI Midwest consortium and Takotsubo cardiomyopathy research program and a widely published clinical investigator in STEMI care.

Prof. Dr. Leor Perl, MD

Director of Cardiac Catheterization Institute

Director of Complex Cardiac Interventions and Chief Innovation Officer at Rabin Medical Center. Graduate of the Stanford Biodesign Program.

Suzanne J. Baron, MD, MSc

Director of Interventional Cardiology Research

Director of Interventional Cardiology Research at Massachusetts General Hospital. Holds a Master’s degree in health economics from Harvard School of Public Health. Expert in cardiovascular device impact on healthcare costs and patient-reported outcomes.

Prof. Marco Valgimigli, MD

Deputy Chief Cardiocentro Ticino Institute

Head of Cardiology at Cardiocentro Ticino and Principal Investigator of the TITAN-OMI randomized controlled trial. His research has shaped both European and US clinical practice guidelines on coronary stents, antithrombotic therapy, and vascular access.

Timothy D. Henry, MD

Medical Director of The Carl and Edyth Lindner Center

Leading expert in interventional cardiology and STEMI treatment. Co-founder and principal investigator of the Midwest STEMI Consortium, a registry of more than 20,000 consecutive STEMI activations. Presenting author for the TCT 2025 Late-Breaking Clinical Science on Queen of Hearts.

Matus Horvath

Head of People

Matus leads hiring strategy and culture at Powerful Medical. He previously ran the People Team at Slido, the Slovak SaaS startup later acquired by Cisco — an experience that informs how he builds a high-performing, values-driven team through rapid scaling.

Dr. Timea Kisova, MD

Clinical Research Lead

Timea leads Powerful Medical’s global external validation studies, including the multi-country AI ECG TIMI Study. With a background in biomedical sciences and a medical degree from Barts and The London School of Medicine and Dentistry, she brings the clinical discipline required to generate the prospective, real-world evidence behind every PMcardio module.

Dr. Anthony Demolder, MD, PhD

HF Pathway Lead

Research physician with a PhD on arrhythmias in heritable thoracic aortic disease. He has led international studies at the intersection of cardiology and AI — including earlier work on atrial fibrillation at AZ Sint-Jan Brugge — and now drives Powerful Medical’s heart failure pathway and LVsense™ AI model development.

Dr. Pendell Meyers, MD

ACS Pathway Lead

Emergency medicine physician, prolific educator, and Co-Editor of Dr. Smith’s ECG Blog. He is one of the leading voices behind the Occlusion Myocardial Infarction (OMI) paradigm, the clinical framework that reshaped how heart attacks are identified from the ECG — and which sits at the core of the Queen of Hearts™ model.

Adam Dej

Head of PMcardio for Organizations Engineering

Adam leads engineering for PMcardio for Organizations at Powerful Medical, driving platform architecture, backend systems, and infrastructure behind one of the company’s key growth products. He began programming at 13, entered professional IT at 17, and studied computer security at Comenius University’s Faculty of Mathematics, Physics and Informatics. Known for technical depth across distributed systems, infrastructure, and security, he builds scalable and resilient software with a sharp focus on customer impact. He also champions responsible use of AI and LLMs as force multipliers for modern engineering teams.

Gabriela Rovder Sklencarova

Head of Infrastructure

Gabriela designs the scalable, secure, distributed systems that keep PMcardio running around the clock for clinicians worldwide. She joined from Google, where she was a senior software engineer building core libraries that kept Google’s services resilient against billions of requests, and holds a BA and MA in Computer Science from the University of Cambridge.

Arezou Azar

VP Regulatory

Arezou leads Powerful Medical’s global regulatory strategy across the FDA, EU MDR, and international frameworks. She has been part of nearly every major breakthrough in AI cardiology and is an expert in US and global regulatory strategy, SaMD/digital health launches, with experience at Eko Health, Verily, AliveCor, Cardiologs, and Apple. She specializes in regulatory strategy in high-paced global organizations.

Adam Rafajdus

Head of AI

Adam grew into the Head of AI role from MLOps Engineer over six years at Powerful Medical, bringing deep expertise in deep learning and production-grade system deployment. He leads the team behind the Queen of Hearts™ AI ECG models and was awarded Best Poster at ISCE 2025 for the company’s ECG digitization pipeline.

Mike Wall

VP of Sales

Mike brings more than twenty years at UnitedHealth Group to the table, where he served health plans, employer groups, and public-sector entities as a consultative healthcare sales executive. He combines market intelligence, clinical insight, and financial acumen — the three ingredients needed to bring AI-powered diagnostics into US health systems at scale.

Amani Farid

Head of Strategic Partnerships

Amani leads partnership strategy with a hands-on approach to integration, unlocking long-term value through collaboration and scale. A University of Chicago Law School-trained attorney and former M&A and capital markets associate at two top international law firms, she brings the rare combination of legal precision and commercial execution refined across nearly a decade at Stryker and as VP of Corporate Development at RapidAI — spanning medtech, digital health, and AI-driven diagnostics.

Michal Martonak

Commercial Lead

A mathematician by training, Michal leads commercial strategy, go-to-market, and strategic partnerships with healthcare providers and clinical institutions worldwide. He previously built Powerful Medical’s data and clinical partnerships function, acquiring the large-scale clinical datasets that underpin the company’s certified AI models.

Dr. Jozef Bartunek, MD, PhD

Co-founder and VP Clinical Strategy

Interventional cardiologist and Co-director of the Cardiovascular Center in Aalst, Belgium — one of the world’s leading heart centers. A Fogarty International NIH Fellow at Harvard Medical School and visiting Professor of Medicine at Catholic University Leuven, he has authored more than 240 peer-reviewed publications in heart failure and structural heart disease, and anchors Powerful Medical’s clinical and research strategy.

Simon Rovder

Co-founder and CTO

Simon began his engineering career at Microsoft and holds a Master’s in Informatics from the University of Edinburgh. He built Powerful Medical’s technology organization from zero, scaling it to a 20+ engineer team and leading the platform architecture that powers a CE-certified Class IIb medical device used in hospitals across Europe.

Viktor Jurasek

Co-founder and CPO

Viktor has spent over a decade designing digital products across healthcare and software and has been the design and product force behind PMcardio since the first prototype. He sets the bar for how a clinical-grade product should feel in a physician’s hands — fast, clear, and trustworthy at the point of care.

Felix Bauer

Co-founder and COO

Felix studied at the Technical University of Munich and was part of the TUM Hyperloop team that repeatedly competed and won in Elon Musk’s SpaceX Hyperloop Pod Competition. He brings a rare combination of engineering rigor, regulatory discipline, and operational excellence to the company, leading operations, compliance, certification, quality management, and global market access since day one.

Dr. Robert Herman, MD, PhD

Co-founder and Chief Medical Officer

Robert is a physician-scientist, served on the Research, Digital and Innovation Committee of the European Society of Cardiology. He bridges the worlds of medicine and artificial intelligence, connecting clinicians, AI researchers, and regulators to translate algorithms into clinical practice. Forbes 30 Under 30 Europe 2024.

Martin Herman

Co-founder and CEO

Martin started coding at 14 and moved to Silicon Valley at 18, founding several companies including a US-based startup before returning to Europe with his brother Robert to build Powerful Medical. He comes from a family of doctors, which shaped his conviction that AI belongs wherever it can genuinely save lives. Forbes 30 Under 30 (Europe 2024).

Heart Attacks are #1 cause of death world-wide and killing about 12 milions people a year.

Clinical Definition of Problem

Contrary to popular belief, a heart attacks isn’t a blockage inside of the heart. A heart attack is a blockage of the coronary arteries supplying the heart muscle with oxygenated blood.

So let’s assume you get a blood clot here — it blocks the blood flow downstream, meaning the heart muscle doesn’t get oxygenated blood and heart tissue downstream starts to die.

Clinical Solution​

The way to fix it is relatively simple – doctors put in a stent that opens up the artery and renews blood flow. The latest clinical practice guidelines recommend that this “stenting” happens within 90 minutes from symptom onset.

If you don’t, even if you put in the stent in later, the heart tissue downstream has already been permanently damaged, which reduces the heart’s ability to pump blood. This is the leading cause of heart failure and increases 1-year mortality by two-fold.

Time is muscle.

You have just 90 minutes to diagnose the patient, bring them to the hospital and put in the stent, otherwise there is permanent damage. So problem is, that 1 in 2 heart attacks get initially misdiagnosed at the first point of contact.

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.